CardioExchange Archive

September 22nd, 2014

Selections from Richard Lehman’s Literature Review: September 22nd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include one-year outcomes after thrombus aspiration for MI, the evaluation and treatment of older patients with hypercholesterolemia, and more.

---

May 27th, 2014

Selections from Richard Lehman’s Literature Review: May 27th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include mortality trends in patients with diabetes, cardiovascular remodeling in CAD and HF, and more.

---

December 14th, 2012

CHMP Recommends Against Approval for Mipomersen in Europe

Larry Husten, PHD

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency today recommended that mipomersen (Kynamro; Isis and Genzyme) not be approved for use in Europe. The novel antisense oligonucleotide works by inhibiting the synthesis of apolipoprotein-B and is under development in the United States and Europe for the treatment of familial hypercholesterolemia. CHMP […]

---

December 10th, 2012

Selections from Richard Lehman’s Literature Review: December 10th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a comparison of warfarin and new oral anticoagulants for managing AF and VTE, two studies of a monoclonal antibody to PCSK9 in patients with hypercholesterolemia, and more.

---

October 31st, 2012

PCSK9 Inhibitor Enhances Cholesterol-Lowering Effect of Atorvastatin

Larry Husten, PHD

When added to low-dose atorvastatin, a much-discussed new monoclonal antibody to PCSK9 significantly lowers cholesterol more effectively than atorvastatin alone, according to a phase 2 study published in the New England Journal of Medicine. Earlier this year, in March, the findings of three phase 1 trials demonstrating the cholesterol-lowering effects of the drug in healthy […]

---